

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROFIT WARNING

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wishes to inform the shareholders of the Company and the potential investors that, based on the unaudited consolidated management accounts of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2026 prepared in accordance with Hong Kong Financial Reporting Standards, the Group is expected to record a net profit of approximately RMB340,000,000 for the six months ended 30 June 2026, while the net profit for the six months ended 30 June 2025 is approximately RMB1,893,000,000.

The decrease in net profit is affected by decline in market prices and demand adjustments in the Intermediate products and Bulk medicine segments. In addition, the Finished products segment recorded license fee income of approximately RMB101 million from Novo Nordisk A/S in first half of 2026 while the license fee income from Novo Nordisk A/S in first half of 2025 amounted to approximately RMB1,433 million.

The information in this announcement is only based on the information currently available to the management of the Company. The results of the Group for the six months ended 30 June 2026 have not yet been finalised nor reviewed by the audit committee and auditor. The final results of the Group for the six months ended 30 June 2026 may be different to the information referred in this announcement.

Detailed unaudited interim results of the Group for the six months ended 30 June 2026 will be published in the forthcoming 2026 interim results announcement and 2026 interim report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 19 August 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.